Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C18H25NO |
Molecular Weight | 271.3972 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC3=C(C=C(OC)C=C3)[C@]4(CCCC[C@@]14[H])CCN2C
InChI
InChIKey=MKXZASYAUGDDCJ-CGTJXYLNSA-N
InChI=1S/C18H25NO/c1-19-10-9-18-8-4-3-5-15(18)17(19)11-13-6-7-14(20-2)12-16(13)18/h6-7,12,15,17H,3-5,8-11H2,1-2H3/t15-,17+,18+/m0/s1
Molecular Formula | C18H25NO |
Molecular Weight | 271.3972 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/27139517https://www.ncbi.nlm.nih.gov/pubmed/21311876Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/26226106 | https://www.ncbi.nlm.nih.gov/pubmed/23628523 | https://www.ncbi.nlm.nih.gov/pubmed/24142584
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27139517https://www.ncbi.nlm.nih.gov/pubmed/21311876
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/26226106 | https://www.ncbi.nlm.nih.gov/pubmed/23628523 | https://www.ncbi.nlm.nih.gov/pubmed/24142584
Levomethorphan ( L-stereoisomer of racemethorphan) is an opioid analgesic of the morphinan family that has never been marketed. Levomethorphan is a methylated prodrug of levorphanol, that undergoes hepatic demethylation, converting it to the active form. Levomethorphan (via it’s active form levorphanol)functions as a potent agonist of all three of the opioid receptors, μ, κ (κ1 and κ3 but notably not κ2), and δ, as an NMDA receptor antagonist, and as a serotonin-norepinephrine reuptake inhibitor. Via activation of the KOR, levomethorphan can produce dysphoria and psychotomimetic effects such as dissociation and hallucinations. Levomethorphan is listed under the Single Convention on Narcotic Drugs 1961 and is regulated like morphine in most countries. In the United States it is a Schedule II Narcotic controlled substance.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24142584
Curator's Comment: https://www.ncbi.nlm.nih.gov/pubmed/16634036
Originator
Sources: https://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=19540415&CC=CH&NR=297994A&KC=Ahttps://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=19480415&CC=CH&NR=254106A&KC=A
Curator's Comment: # F. Hoffmann-La Roche & Co., A.-G.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2094124 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19345586 |
3360.0 nM [Ki] | ||
Target ID: CHEMBL287 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15723099 |
205.0 nM [Ki] | ||
Target ID: CHEMBL4787 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2897648 |
|||
Target ID: CHEMBL2094124 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19345586 |
3360.0 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21311876 |
Primary | Unknown Approved UseUnknown |
||
PubMed
Title | Date | PubMed |
---|---|---|
Differential effects of morphinan drugs on haloperidol-induced catalepsy in rats: a comparative study with an N-methyl-D-aspartate antagonist. | 1991 Mar-Apr |
|
[Dextromethorphan enhances analgesic activity of propacetamol--experimental study]. | 2005 |
|
Phenotypical expression of CYP2D6 in amerindians of tepehuano origin from Durango, Mexico. | 2005 |
|
Epigenetic silencing of DSC3 is a common event in human breast cancer. | 2005 |
|
High-throughput screening of inhibitory potential of nine cytochrome P450 enzymes in vitro using liquid chromatography/tandem mass spectrometry. | 2005 |
|
Dextromethorphan psychosis, dependence and physical withdrawal. | 2005 Dec |
|
MK-801 and dextromethorphan block microglial activation and protect against methamphetamine-induced neurotoxicity. | 2005 Jul 19 |
|
Evaluation of dextromethorphan metabolism using hepatocytes from CYP2D6 poor and extensive metabolizers. | 2005 Jun |
|
Cytochrome P450 2D6 (CYP2D6) inhibitory constituents of Catharanthus roseus. | 2005 Jun |
|
Dextromethorphan-induced delirium and possible methadone interaction. | 2005 Mar |
|
Recombinant production of human microsomal cytochrome P450 2D6 in the methylotrophic yeast Pichia pastoris. | 2005 Nov |
|
Side effects of dextromethorphan abuse, a case series. | 2005 Sep |
|
Cluster formation as a tool for development in Medicon Valley. | 2006 Jan-Feb |
|
Dextromethorphan-induced neurologic illness in a patient with negative toxicology findings. | 2006 Jun 27 |
|
Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis. | 2006 May |
|
Mesenteric artery clamping/unclamping-induced acute lung injury is attenuated by N-methyl-D-aspartate antagonist dextromethorphan. | 2006 Nov-Dec |
|
Co-administration of dextromethorphan with methamphetamine attenuates methamphetamine-induced rewarding and behavioral sensitization. | 2006 Sep |
|
Immunohistological assessment of the synovial tissue in small joints in rheumatoid arthritis: validation of a minimally invasive ultrasound-guided synovial biopsy procedure. | 2007 |
|
Cough mixture abuse as a novel cause of folate deficiency: a prospective, community-based, controlled study. | 2007 Apr |
|
Sex differences in the potency of kappa opioids and mixed-action opioids administered systemically and at the site of inflammation against capsaicin-induced hyperalgesia in rats. | 2007 Apr |
|
Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17. | 2007 Aug |
|
Treatment of the common cold. | 2007 Feb 15 |
|
A placebo double-blind pilot study of dextromethorphan for problematic behaviors in children with autism. | 2007 Jan |
|
Oral administration of dextromethorphan does not produce neuronal vacuolation in the rat brain. | 2007 Jul |
|
In vitro interaction cocktail assay for nine major cytochrome P450 enzymes with 13 probe reactions and a single LC/MSMS run: analytical validation and testing with monoclonal anti-CYP antibodies. | 2007 Jul |
|
Free energies of binding of R- and S-propranolol to wild-type and F483A mutant cytochrome P450 2D6 from molecular dynamics simulations. | 2007 Jul |
|
[Simultaneous determination of the inhibitory potency of compounds on the activity of five cytochrome P-450 enzymes using a cocktail probe substrates method]. | 2007 Jun |
|
Challenges for Australia's Bio/Nanopharma Policies: trade deals, public goods and reference pricing in sustainable industrial renewal. | 2007 Jun 1 |
|
Validated method for rapid inhibition screening of six cytochrome P450 enzymes by liquid chromatography-tandem mass spectrometry. | 2007 Jun 1 |
|
Development and full validation of six inhibition assays for five major cytochrome P450 enzymes in human liver microsomes using an automated 96-well microplate incubation format and LC-MS/MS analysis. | 2007 May 9 |
|
Prior exposure to uninfected mosquitoes enhances mortality in naturally-transmitted West Nile virus infection. | 2007 Nov 14 |
|
Effect of sodium ozagrel on the activity of rat CYP2D6. | 2007 Nov 14 |
|
Dextromethorphan: a review of N-methyl-d-aspartate receptor antagonist in the management of pain. | 2007 Spring |
|
Ubiquitous computing for remote cardiac patient monitoring: a survey. | 2008 |
|
Mechanical aspects of a multidirectional, angular stable osteosynthesis system and comparison with four conventional systems. | 2008 Apr |
|
Sex differences in NMDA antagonist enhancement of morphine antihyperalgesia in a capsaicin model of persistent pain: comparisons to two models of acute pain. | 2008 Apr |
|
Effects of common antitussive drugs on the hERG potassium channel current. | 2008 Dec |
|
Sigma ligands, but not N-methyl-D-aspartate antagonists, reduce levodopa-induced dyskinesias. | 2008 Jan 8 |
|
Anti-inflammatory effects of dimemorfan on inflammatory cells and LPS-induced endotoxin shock in mice. | 2008 Jul |
|
Functional expression and comparative characterization of nine murine cytochromes P450 by fluorescent inhibition screening. | 2008 Jul |
|
Life-threatening dextromethorphan intoxication associated with interaction with amitriptyline in a poor CYP2D6 metabolizer: a single case re-exposure study. | 2008 Jul |
|
Effects of repeated cycles of sterilisation on the mechanical characteristics of titanium miniplates for osteosynthesis. | 2008 Sep |
|
Effect of fenofibrate on microcirculation and wound healing in healthy and diabetic mice. | 2009 |
|
Dextromethorphan reduces oxidative stress and inhibits atherosclerosis and neointima formation in mice. | 2009 Apr 1 |
|
The diagnostic role of glycosaminoglycans in pleural effusions: a pilot study. | 2009 Feb 18 |
|
Amyotrophic lateral sclerosis. | 2009 Feb 3 |
|
Characterization of retrieved orthodontic miniscrew implants. | 2009 Jan |
|
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study. | 2009 Jan |
|
Retrospective analysis of titanium plate-retained prostheses placed after total rhinectomy. | 2009 Jan-Feb |
|
[Bone anchored hearing aids (BAHA)]. | 2009 Mar |
Sample Use Guides
Dextromethorphan -- 15-30 mg 3 to 4 times per day (cough)
Dextromethorphan -- 20-30 mg twice daily (pseudobulbar affect)
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21311876
Liver microsomes from individual male dark agouti (DA) rats (n=4, 6 weeks old, around 125 g mean weight) were prepared by ultracentrifugation. For the in vitro experiments with rat and human liver microsomes, the reaction mixture consisted of 0.1 M potassium phosphate buffer (pH 7.4) with an NADPH generating system (1.3 mM NADP, 3.3 mM G-6-P, 0.4 U/ mL G-6-PDH, 3.3 mM MgCl2), 50 μM substrate (dextromethorphan or levomethorphan), and 0.5 mg protein/mL microsomes (rat or human liver microsomes) in a final volume of 200 μL. Dextromethorphan and levomethorphan were dissolved in methanol, and the final concentration of the organic solvent was 0.1%. The incubation was started by adding the microsomal fraction and then continued for 0, 5, 10, or 20 min. The reaction was terminated by adding an equal volume of a mixed organic solution of 50% acetonitrile and 50% methanol, including 10 μM levallorphan (IS), and vigorous shaking.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:06:28 GMT 2023
by
admin
on
Fri Dec 15 16:06:28 GMT 2023
|
Record UNII |
7ZZ22K9QE6
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C67413
Created by
admin on Fri Dec 15 16:06:28 GMT 2023 , Edited by admin on Fri Dec 15 16:06:28 GMT 2023
|
||
|
DEA NO. |
9210
Created by
admin on Fri Dec 15 16:06:28 GMT 2023 , Edited by admin on Fri Dec 15 16:06:28 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB08478MIG
Created by
admin on Fri Dec 15 16:06:28 GMT 2023 , Edited by admin on Fri Dec 15 16:06:28 GMT 2023
|
PRIMARY | |||
|
LEVOMETHORPHAN
Created by
admin on Fri Dec 15 16:06:28 GMT 2023 , Edited by admin on Fri Dec 15 16:06:28 GMT 2023
|
PRIMARY | |||
|
148
Created by
admin on Fri Dec 15 16:06:28 GMT 2023 , Edited by admin on Fri Dec 15 16:06:28 GMT 2023
|
PRIMARY | |||
|
146176
Created by
admin on Fri Dec 15 16:06:28 GMT 2023 , Edited by admin on Fri Dec 15 16:06:28 GMT 2023
|
PRIMARY | |||
|
C83875
Created by
admin on Fri Dec 15 16:06:28 GMT 2023 , Edited by admin on Fri Dec 15 16:06:28 GMT 2023
|
PRIMARY | |||
|
204-751-7
Created by
admin on Fri Dec 15 16:06:28 GMT 2023 , Edited by admin on Fri Dec 15 16:06:28 GMT 2023
|
PRIMARY | |||
|
DTXSID20872403
Created by
admin on Fri Dec 15 16:06:28 GMT 2023 , Edited by admin on Fri Dec 15 16:06:28 GMT 2023
|
PRIMARY | |||
|
7ZZ22K9QE6
Created by
admin on Fri Dec 15 16:06:28 GMT 2023 , Edited by admin on Fri Dec 15 16:06:28 GMT 2023
|
PRIMARY | |||
|
CHEMBL1908323
Created by
admin on Fri Dec 15 16:06:28 GMT 2023 , Edited by admin on Fri Dec 15 16:06:28 GMT 2023
|
PRIMARY | |||
|
m6790
Created by
admin on Fri Dec 15 16:06:28 GMT 2023 , Edited by admin on Fri Dec 15 16:06:28 GMT 2023
|
PRIMARY | Merck Index | ||
|
100000082278
Created by
admin on Fri Dec 15 16:06:28 GMT 2023 , Edited by admin on Fri Dec 15 16:06:28 GMT 2023
|
PRIMARY | |||
|
125-70-2
Created by
admin on Fri Dec 15 16:06:28 GMT 2023 , Edited by admin on Fri Dec 15 16:06:28 GMT 2023
|
PRIMARY | |||
|
5362449
Created by
admin on Fri Dec 15 16:06:28 GMT 2023 , Edited by admin on Fri Dec 15 16:06:28 GMT 2023
|
PRIMARY | |||
|
1362359
Created by
admin on Fri Dec 15 16:06:28 GMT 2023 , Edited by admin on Fri Dec 15 16:06:28 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
APPROXIMATE PURE ANHYDROUS DRUG CONTENT (IN PERCENT)
|
||
|
SALT/SOLVATE -> PARENT |
APPROXIMATE PURE ANHYDROUS DRUG CONTENT (IN PERCENT)
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> IMPURITY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |